Ohad S. Bentur

机构：Summit Medical Group (United States) · ORCID：0000-0002-5976-7121

发表论文 57 篇 · 总被引 445 次 · h-index 12

代表论文

• Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment (2022 · eJHaem · 被引 20)
• Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies (2023 · Clinical Lymphoma Myeloma & Leukemia · 被引 14)
• Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial (2024 · Blood · 被引 13)
• Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction – A post hoc analysis of the cel-02 phase IIa study (2023 · American Heart Journal · 被引 12)
• Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (2024 · Frontiers in Oncology · 被引 10)
• Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study (2023 · Clinical Lymphoma Myeloma & Leukemia · 被引 10)